Characteristics of rheumatoid arthritis patients initiating therapy with abatacept, other biologics, and non-biologic disease-modifying anti-rheumatic drugs

被引：0
|
作者：
Hoffman, Veena [1 ]
Simon, Teresa A. [2 ]
Liu, Nan [3 ]
Lin, Nancy D. [3 ]
机构：
[1] Optum, Ann Arbor, MI USA
[2] Bristol Myers Squibb, Pennington, NJ USA
[3] Optum, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2017年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
459
引用
收藏
页码：278 / 278
页数：1
相关论文
共 50 条
  • [11] SUBCUTANEOUS ABATACEPT IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: PHARMACOKINETICS, EFFICACY AND SAFETY
    Ruperto, Nicolino
    Lovell, Daniel J.
    Tzaribachev, Nikolay
    Vega-Cornejo, Gabriel
    Louw, Ingrid
    Berman, Alberto
    Calvo, Inmaculada
    Cuttica, Ruben
    Horneff, Gerd
    Avila-Zapata, Francisco
    Anton, Jordi
    Cimaz, Rolando
    Solau-Gervais, Elisabeth
    Joos, Rik
    Espada, Graciela
    Li, Xiaohui
    Nys, Marleen
    Wong, Robert
    Banerjee, Subhashis
    Brunner, Hermine I.
    Martini, Alberto
    [J]. RHEUMATOLOGY, 2017, 56 : 40 - 41
  • [12] Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
    Choy, Ernest H.
    [J]. RHEUMATOLOGY, 2019, 58 : 51 - 55
  • [13] Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
    Xie, Fenglong
    Chen, Lang
    Levitan, Emily
    Muntner, Paul M.
    Curtis, Jeffrey R.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [14] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    [J]. SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [15] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    [J]. CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [16] The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs
    Radner, Helga
    Yoshida, Kazuki
    Frits, Michelle
    Iannaccone, Christine
    Shadick, Nancy A.
    Weinblatt, Michael
    Smolen, Josef S.
    Solomon, Daniel H.
    [J]. RHEUMATOLOGY, 2015, 54 (11) : 2076 - 2084
  • [17] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, E.
    Ito, S.
    Kurosawa, Y.
    Taniguchi, S.
    Kobayashi, D.
    Abe, A.
    Otani, H.
    Nakazono, K.
    Murasawa, A.
    Narita, I.
    Ishikawa, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
  • [18] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [19] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [20] ADHERENCE TO BIOLOGIC AND CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Mishra, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S198 - S198
12345